Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study

BMC Hematology

Volumn 15, Issue 1, 2015, Pages

  Kaddam, Lamis ^a   FdleAlmula, Imad ^a   Eisawi, Omer Ali ^b   Abdelrazig, Haydar Awad ^b   Elnimeiri, Mustafa ^a   Lang, Florian ^c   Saeed, Amal M ^d  

^a AL NEELAIN UNIVERSITY   (Sudan)

^b Military Hospital   (Sudan)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; ERYTHROPOIETIN; GUM ARABIC; HEMOGLOBIN F;

ADOLESCENT; ADULT; ARTICLE; BLOATING; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; LABORATORY TEST; LEG ULCER; LEUKOCYTE COUNT; MALE; MEAN CORPUSCULAR VOLUME; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; SENEGALIA SENEGAL; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; TREATMENT DURATION; VOMITING;

EID: 85018739169     PISSN: None     EISSN: 20521839     Source Type: Journal    
DOI: 10.1186/s12878-015-0040-6     Document Type: Article

References (37)

1. Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program 2006;58-62.
2. Lang E, Lang F. Triggers, inhibitors, mechanisms, and significance of eryptosis: The suicidal erythrocyte death. Biomed Res Int. 2015;2015:513518.
3. Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol. 2009;82(4):315-21.
4. Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FI, Bassi SC, Santis GC, et al. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: A single-center experience in Brazil. Sao Paulo Med J. 2013;131(4):238-43.
5. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27.
6. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-4.
7. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009;62-9. doi: 10.1182/asheducation-2009.1.62.
8. Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, et al. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013;88(11):E255-60.
9. Diallo DA, Guindo A. Sickle cell disease in sub-Saharan Africa: Stakes and strategies for control of the disease. Curr Opin Hematol. 2014;21(3):210-4.
10. Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790-7.
11. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med. 1992;327(8):569-70.
12. Fathallah H, Weinberg RS, Galperin Y, Sutton M, Atweh GF. Role of epigenetic modifications in normal globin gene regulation and butyratemediated induction of fetal hemoglobin. Blood. 2007;110(9):3391-7.
13. Hines P, Dover GJ, Resar LM. Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer. 2008;50(2):357-9.
14. Resar LM, Segal JB, Fitzpatric LK, Friedmann A, Brusilow SW, Dover GJ. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 2002;24(9):737-41.
15. Ali BH, Ziada A, Blunden G. Biological effects of gum arabic: A review of some recent research. Food Chem Toxicol. 2009;47(1):1-8.
16. Babiker R, Merghani TH, Elmusharaf K, Badi RM, Lang F, Saeed AM. Effects of Gum Arabic ingestion on body mass index and body fat percentage in healthy adult females: two-arm randomized, placebo controlled, doubleblind trial. Nutr J. 2012;11:111.
17. Ballal A, Bobbala D, Qadri SM, Foller M, Kempe D, Nasir O, et al. Anti-malarial effect of gum arabic. Malar J. 2011;10:139.
18. Tulung B, Remesy C, Demigne C. Specific effect of guar gum or gum arabic on adaptation of cecal digestion to high fiber diets in the rat. J Nutr. 1987;117(9):1556-61.
19. Matsumoto N, Riley S, Fraser D, Al-Assaf S, Ishimura E, Wolever T, et al. Butyrate modulates TGF-beta1 generation and function: Potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? Kidney Int. 2006;69(2):257-65.
20. Nasir O. Renal and extrarenal effects of gum arabic (Acacia senegal)-what can be learned from animal experiments? Kidney Blood Press Res. 2013;37(4-5):269-79.
21. Ali BH, Al-Husseni I, Beegam S, Al-Shukaili A, Nemmar A, Schierling S, et al. Effect of gum arabic on oxidative stress and inflammation in adenineinduced chronic renal failure in rats. PLoS One. 2013;8(2):e55242.
22. Nasir O, Umbach AT, Rexhepaj R, Ackermann TF, Bhandaru M, Ebrahim A, et al. Effects of gum arabic (Acacia senegal) on renal function in diabetic mice. Kidney Blood Press Res. 2012;35(5):365-72.
23. Ali BH, Al ZaGçöabi M, Ramkumar A, Yasin J, Nemmar A. Anemia in adenine-induced chronic renal failure and the influence of treatment with gum acacia thereon. Physiol Res. 2014;63(3):351-8.
24. Ali BH, Beegam S, Al Lawati I, Waly MI, Nemmar A. Comparative efficacy of three brands of gum arabic on adenineGçôinduced chronic renal failure in rats. Physiol Res. 2013;62(1):47-56.
25. de FL, Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica. 2004;89(3):348-56.
26. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood. 2008;112(10):3927-38.
27. Orringer EP, Blythe DS, Johnson AE, Phillips Jr G, Dover GJ, Parker JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood. 1991;78(1):212-6.
28. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628-32.
29. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004; 103(6):2039-45.
30. Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol. 1997;98(4):838-44.
31. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatr Hydroxyurea Group Blood. 1999;94(5):1550-4.
32. Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol. 2003;72(2):121-6.
33. Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in beta-thalassaemia intermedia and HbE/beta-thalassaemia. Br J Haematol. 2013;161(4):587-93.
34. Bartolucci P, Brugnara C, Teixeira-Pinto A, Pissard S, Moradkhani K, Jouault H, et al. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012;120(15):3136-41.
35. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46(1):105-10.
36. Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood. 1993;81(1):9-14.
37. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993;328(2):73-80.